|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Elan Pharmaceuticals |
|---|---|
| Information provided by: | Elan Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00076544 |
Purpose
The purpose of this open-label study is to give chronic severe pain patients with existing intrathecal pump systems access to ziconotide.
| Condition | Intervention | Phase |
|---|---|---|
|
Pain |
Drug: Ziconotide |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Safety Study |
| Official Title: | An Open-Label, Long-Term, Multi-Center, Intrathecal Ziconotide (PRIALT) Effectiveness and Safety Trial (ZEST) in Patients With Chronic Severe Pain |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Show 65 Study Locations
More Information
| Study ID Numbers: | ELN92045-501 |
| Study First Received: | January 26, 2004 |
| Last Updated: | February 18, 2009 |
| ClinicalTrials.gov Identifier: | NCT00076544 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Intrathecal |
|
Ziconotide Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Calcium Channel Blockers Cardiovascular Agents Neuroprotective Agents Protective Agents Pharmacologic Actions |
Membrane Transport Modulators Sensory System Agents Analgesics, Non-Narcotic Therapeutic Uses Peripheral Nervous System Agents Analgesics Central Nervous System Agents |